T1	Participants 79 146	patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial
T2	Participants 443 505	large cohort of patients presenting across the spectrum of ACS
T3	Participants 583 685	patients randomized to atorvastatin 80 mg or pravastatin 40 mg after ACS in the PROVE IT-TIMI 22 trial
